Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
Moodys
Mallinckrodt
AstraZeneca

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,696,236

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,696,236 protect, and when does it expire?

Patent 7,696,236 protects ESBRIET and is included in one NDA.

This patent has eighteen patent family members in thirteen countries.

Summary for Patent: 7,696,236
Title:Method of providing pirfenidone therapy to a patient
Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
Inventor(s): Bradford; Williamson Z. (Ross, CA)
Assignee: InterMune, Inc. (Brisbane, CA)
Application Number:12/427,532
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,696,236
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,696,236

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech Inc ESBRIET pirfenidone CAPSULE;ORAL 022535-001 Oct 15, 2014 RX Yes Yes   Start Trial   Start Trial DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,696,236

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 506060   Start Trial
Canada 2667654   Start Trial
Cyprus 1111699   Start Trial
Germany 602007014113   Start Trial
Denmark 2124945   Start Trial
European Patent Office 2124945   Start Trial
European Patent Office 2338489   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Baxter
Harvard Business School
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.